JP2015516418A5 - - Google Patents

Download PDF

Info

Publication number
JP2015516418A5
JP2015516418A5 JP2015511510A JP2015511510A JP2015516418A5 JP 2015516418 A5 JP2015516418 A5 JP 2015516418A5 JP 2015511510 A JP2015511510 A JP 2015511510A JP 2015511510 A JP2015511510 A JP 2015511510A JP 2015516418 A5 JP2015516418 A5 JP 2015516418A5
Authority
JP
Japan
Prior art keywords
formulation
range
formula
active pharmaceutical
pharmaceutical ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015511510A
Other languages
English (en)
Japanese (ja)
Other versions
JP6276756B2 (ja
JP2015516418A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/038770 external-priority patent/WO2013169520A1/en
Publication of JP2015516418A publication Critical patent/JP2015516418A/ja
Publication of JP2015516418A5 publication Critical patent/JP2015516418A5/ja
Application granted granted Critical
Publication of JP6276756B2 publication Critical patent/JP6276756B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015511510A 2012-05-07 2013-04-30 1,1−ジメチルエチル[(1s)−1−{[(2s,4r)−4−(7−クロロ−4メトキシイソキノリン−1−イルオキシ)−2−({(1r,2s)−1−[(シクロプロピルスルホニル)カルバモイル]−2−エテニルシクロプロピル}カルバモイル)ピロリジン−1−イル]カルボニル}−2,2−ジメチルプロピル]カルバメートの可溶化カプセル製剤 Expired - Fee Related JP6276756B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643454P 2012-05-07 2012-05-07
US61/643,454 2012-05-07
PCT/US2013/038770 WO2013169520A1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Publications (3)

Publication Number Publication Date
JP2015516418A JP2015516418A (ja) 2015-06-11
JP2015516418A5 true JP2015516418A5 (enExample) 2016-05-26
JP6276756B2 JP6276756B2 (ja) 2018-02-07

Family

ID=48428670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511510A Expired - Fee Related JP6276756B2 (ja) 2012-05-07 2013-04-30 1,1−ジメチルエチル[(1s)−1−{[(2s,4r)−4−(7−クロロ−4メトキシイソキノリン−1−イルオキシ)−2−({(1r,2s)−1−[(シクロプロピルスルホニル)カルバモイル]−2−エテニルシクロプロピル}カルバモイル)ピロリジン−1−イル]カルボニル}−2,2−ジメチルプロピル]カルバメートの可溶化カプセル製剤

Country Status (33)

Country Link
US (1) US20130302414A1 (enExample)
EP (1) EP2846780B1 (enExample)
JP (1) JP6276756B2 (enExample)
KR (1) KR20150004921A (enExample)
CN (1) CN104363899A (enExample)
AR (1) AR090954A1 (enExample)
AU (1) AU2013260005B2 (enExample)
BR (1) BR112014027676A2 (enExample)
CA (1) CA2872765A1 (enExample)
CL (1) CL2014003012A1 (enExample)
CO (1) CO7141457A2 (enExample)
CY (1) CY1120756T1 (enExample)
DK (1) DK2846780T3 (enExample)
EA (1) EA028749B1 (enExample)
ES (1) ES2688817T3 (enExample)
HR (1) HRP20181583T1 (enExample)
IL (1) IL235466B (enExample)
LT (1) LT2846780T (enExample)
MX (1) MX358545B (enExample)
MY (1) MY171378A (enExample)
NZ (1) NZ630248A (enExample)
PE (1) PE20142439A1 (enExample)
PH (1) PH12014502405A1 (enExample)
PL (1) PL2846780T3 (enExample)
PT (1) PT2846780T (enExample)
RS (1) RS57881B1 (enExample)
SG (1) SG11201406964QA (enExample)
SI (1) SI2846780T1 (enExample)
SM (1) SMT201800506T1 (enExample)
TW (1) TWI577392B (enExample)
UY (1) UY34785A (enExample)
WO (1) WO2013169520A1 (enExample)
ZA (1) ZA201408967B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150119317A1 (en) * 2012-05-07 2015-04-30 Bristol-Myers Squibb Company Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
CN117281790A (zh) * 2018-12-19 2023-12-26 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
UA78689C2 (en) * 2000-10-31 2007-04-25 Boehringer Ingelheim Pharma Pyranone-based pharmaceutical composition (variants)
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20110229438A1 (en) * 2008-10-09 2011-09-22 Anadys Pharmaceuticals, Inc. Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Similar Documents

Publication Publication Date Title
JP2015516418A5 (enExample)
RU2709612C2 (ru) САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ
JP6276756B2 (ja) 1,1−ジメチルエチル[(1s)−1−{[(2s,4r)−4−(7−クロロ−4メトキシイソキノリン−1−イルオキシ)−2−({(1r,2s)−1−[(シクロプロピルスルホニル)カルバモイル]−2−エテニルシクロプロピル}カルバモイル)ピロリジン−1−イル]カルボニル}−2,2−ジメチルプロピル]カルバメートの可溶化カプセル製剤
EP3023099B1 (en) Self-emulsifying composition of -3 fatty acid
RU2018119295A (ru) Фармацевтические составы для местного применения для лечения связанных с воспалением состояний
CO6311066A2 (es) Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas
JP2015038155A5 (enExample)
ES2948444T3 (es) Composiciones que comprenden 15-HEPE
TWI654981B (zh) 包含度他雄胺和丙二醇單月桂酸酯的醫藥組成物及其製備方法
BRPI0808945A2 (pt) Composição
RU2015115127A (ru) Жидкие лекарственные композиции апиксабана
RU2016119746A (ru) Стабильный состав инсулина глулизин
JP2015504924A5 (enExample)
JP2016503030A5 (enExample)
JP2015523361A5 (ja) 低分子薬の非経口注射用の安定な製剤
AR103653A1 (es) Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen
JP2025061087A (ja) 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法
AU2015270187A1 (en) Oral pharmaceutical composition of isotretinoin
RU2017110076A (ru) Фармацевтическая композиция и способы
JPH04217912A (ja) 水難溶性薬物の医薬組成物
CA2690490A1 (en) Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
JP5750278B2 (ja) カンデサルタンシレキセチルのカプセル充填用組成物
JP6082503B1 (ja) ソフトカプセル剤
JP2006522011A (ja) 安定なカルプロフェン組成物
JP2021504479A5 (enExample)